

The Real TADS Suicide Data

	At 12 Weeks		12 to 36 Weeks		Total	
	Suicidal Ideation	Suicide Attempts	Suicidal Ideation	Suicide Attempts	Suicidal Ideation	Suicide Attempts
Non-Drug						
Placebo/Open	3	0	0	0	3	0
CBT	4	1	0	0	4	1
Fluoxetine						
Placebo/Open	2	0	1	6	3	6
CBT				2		2
Fluoxetine	9	3	1	3	10	6
Fluoxetine plus CBT	3	2	3	1	6	3
Totals						
Non-Drug	7	1	0	0	7	1
Drug	14	5	6	12	19	17

There were 439 youth ages 12-17 randomized into the TADS study, into one of four groups: placebo (112); CBT (111); fluoxetine (109); and fluoxetine plus CBT (107). Eight of the placebo patients were exposed to fluoxetine during the initial 12 weeks. During the 24-week followup, there were a number of patients in the placebo/open group prescribed fluoxetine, and some from the CBT group as well. However, the extent of this exposure to fluoxetine during the followup isn't clear from the published data. Source: Vitiello, "Suicidal Events in the Treatment for Adolescents with Depression," *J Clin Psychiatry* 70 (2009):741-7.